News brief­ing: No­var­tis' Zol­gens­ma hits block­buster sta­tus, trig­ger­ing $80M mile­stone; Caris rais­es $310M for ge­nom­ic pro­fil­ing ex­pan­sion

No­var­tis re­port­ed that Zol­gens­ma earned $291 mil­lion in Q3, which puts the SMA gene ther­a­py square­ly in the block­buster cat­e­go­ry. That, in turn, is pay­ing ben­e­fits to Re­genxbio, which pro­vid­ed the NAV AAV9 vec­tor used by Zol­gens­ma.

The biotech $RGNX re­port­ed Tues­day morn­ing that it is get­ting an $80 mil­lion mile­stone pay­ment from No­var­tis, which now has earned more than $1 bil­lion cu­mu­la­tive­ly from the new gene ther­a­py fran­chise. And with large per­cent­ages of new­borns now be­ing screened for the rare, lethal ail­ment, the fran­chise can con­tin­ue to grow.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.